Access and Evidence
Adaptive Licensing: How it Impacts Pharma and the Patient
With the announcement by the EMA of its adaptive licensing scheme, we interview Richard Barker, Director of CASMI, who was closely involved with the project.
More Access and Evidence Articles
Commercial
Are You Keeping Well? Prioritizing Prevention through an Integrated Approach
Pharmaceutical companies are perfectly placed to leverage their knowledge and resources to influence patient behavioral change. Putting the right incentives in place is critical to ensure investment for long-term prevention.
Commercial
Plus Pill: A Shift in Pharma’s Mindset
The 21st century pharma company is no longer solely a provider of molecules. To survive in the new reality, the industry must change its mindset and offer services, putting the customer at the center of their activities.
Commercial
Top honour to pharma exec who believes in "delivering more than just a pill"
Lundbeck’s Patrick Cashman wins eyeforpharma Lifetime Achievement Award for always putting the patient first
Access and Evidence
A New Era of Reimbursement in France
eyeforpharma interviews the President of HAS
Access and Evidence
Real World Data: Collaboration is Key to Success
By now everybody appreciates the relevance of real-world data. The challenge that is left is linking snapshots of fragmented information and creating a comprehensive picture of patient journey.
Access and Evidence
Realising the Potential of Joint Working: Towards an Ideal Partnership.
Exclusive research conducted by Strategic North indicates that huge misperceptions exist between industry and the NHS that are placing a stranglehold on successful joint working. Deirdre Coleman reviews the current mindset and explores an ideal model for partnership.
Access and Evidence
Embracing the Age of Data-Driven Medicine
Deirdre Coleman assesses the challenges Real World Evidence poses for pharma and the path towards gaining meaningful insight from its usage.
Access and Evidence
Real World Data: Real World Opportunities
Supplementing information gathered in randomised clinical trials (RCT), optimising RCT design, and streamlining R&D are just some of the opportunities that come with big data, but successful implementation of RWD depends on breaking down data silos, and devising an optimum strategy.
Access and Evidence
Real World Data: Promises and Challenges
Big data, big promises, but getting the complete picture needs multiple sources of information. Real World Data (RWD), randomized clinical trials (RCTs), and small-scale, focus-group-based surveys are not members of opposite teams, but pieces of the same puzzle.